• LoDoCo2: Low-Dose Colchicine in Coronary Disease Trial Discussion
    Sorry, the video is currently unavailable.

    Drs. Ron and Waksman and Aernoud Fiolet discuss the LoDoCo 2 trial, which was presented at the European Society of Cardiology 2020 virtual congress on Aug. 31, 2020. The study found that low-dose colchicine reduces the risk of cardiovascular events in patients with chronic coronary disease.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details